PL333370A1 - Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels - Google Patents

Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels

Info

Publication number
PL333370A1
PL333370A1 PL97333370A PL33337097A PL333370A1 PL 333370 A1 PL333370 A1 PL 333370A1 PL 97333370 A PL97333370 A PL 97333370A PL 33337097 A PL33337097 A PL 33337097A PL 333370 A1 PL333370 A1 PL 333370A1
Authority
PL
Poland
Prior art keywords
oxygenase
cyclo
vessels
inhibitors
acting against
Prior art date
Application number
PL97333370A
Other versions
PL191793B1 (en
Inventor
Jaime L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PL333370A1 publication Critical patent/PL333370A1/en
Publication of PL191793B1 publication Critical patent/PL191793B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL333370A 1996-11-19 1999-04-30 Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels PL191793B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
PL333370A1 true PL333370A1 (en) 1999-12-06
PL191793B1 PL191793B1 (en) 2006-07-31

Family

ID=21859277

Family Applications (2)

Application Number Title Priority Date Filing Date
PL97373973A PL194717B1 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as agents acting against overgrowth of vessels
PL333370A PL191793B1 (en) 1996-11-19 1999-04-30 Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL97373973A PL194717B1 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as agents acting against overgrowth of vessels

Country Status (19)

Country Link
EP (1) EP0941080A2 (en)
JP (1) JP2001505564A (en)
KR (1) KR20000053362A (en)
CN (1) CN1247470A (en)
AU (1) AU730211B2 (en)
BR (1) BR9713522A (en)
CA (1) CA2270469C (en)
CZ (1) CZ176899A3 (en)
ID (1) ID21979A (en)
IL (1) IL129604A (en)
NO (1) NO992309D0 (en)
NZ (1) NZ335853A (en)
PL (2) PL194717B1 (en)
RO (1) RO118566B1 (en)
RU (1) RU2268716C2 (en)
SK (1) SK59999A3 (en)
TR (1) TR199901703T2 (en)
UA (1) UA70294C2 (en)
WO (1) WO1998022101A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2002533416A (en) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー Methods of using cyclooxygenase-2 inhibitors and one or more antineoplastic agents as combination therapy in the treatment of neoplasia
WO2000053149A2 (en) * 1999-03-10 2000-09-14 G.D. Searle & Co. Method and composition for administering a cyclooxygenase-2 inhibitor
CA2380078C (en) * 1999-07-29 2008-05-06 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides
PT1282418E (en) * 2000-05-19 2005-10-31 Applied Research Systems USE OF PYRAZOLE DERIVATIVES FOR THE TREATMENT OF INFERTILITY
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (en) * 2001-12-28 2007-02-27 씨제이 주식회사 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor
CA2492387A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
KR100484525B1 (en) * 2002-10-15 2005-04-20 씨제이 주식회사 Isothiazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
AT504159A1 (en) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
RU2475257C1 (en) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Preparation for increasing organism adaptability to extreme conditions
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2152792C (en) * 1993-01-15 2000-02-15 Stephen R. Bertenshaw Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
RU2139281C1 (en) * 1993-11-30 1999-10-10 Джи Ди Сирл энд Компани Pyrazolyl-substituted benzenesulfoneamide or its pharmaceutically acceptable salt, method of treatment of patients with inflammation or inflammation-associated diseases
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
CA2206978A1 (en) * 1994-12-21 1996-06-27 Merck Frosst Canada Inc. Diaryl-2-(5h)-furanones as cox-2 inhibitors
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
NO992309L (en) 1999-05-12
NO992309D0 (en) 1999-05-12
EP0941080A2 (en) 1999-09-15
PL194717B1 (en) 2007-06-29
PL191793B1 (en) 2006-07-31
UA70294C2 (en) 2004-10-15
CZ176899A3 (en) 1999-10-13
CA2270469C (en) 2007-04-10
ID21979A (en) 1999-08-19
IL129604A (en) 2004-08-31
RO118566B1 (en) 2003-07-30
WO1998022101A2 (en) 1998-05-28
IL129604A0 (en) 2000-02-29
JP2001505564A (en) 2001-04-24
RU2268716C2 (en) 2006-01-27
CA2270469A1 (en) 1998-05-28
CN1247470A (en) 2000-03-15
NZ335853A (en) 2002-02-01
BR9713522A (en) 2000-03-21
AU730211B2 (en) 2001-03-01
AU7298298A (en) 1998-06-10
TR199901703T2 (en) 2000-07-21
SK59999A3 (en) 2000-01-18
KR20000053362A (en) 2000-08-25
WO1998022101A3 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
PL333370A1 (en) Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels
AU5896699A (en) Access system for branched vessels and methods of use
EP0519748A3 (en) Peptidyl derivatives as inhibitors of interleukin-1b converting enzyme
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL327569A1 (en) Promedications of thrombosin inhibitors
ZA9710907B (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phospohorylase inhibitors
AU7230096A (en) System for anchoring ships
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
SG67371A1 (en) Method of preventing pitting corrosion
AU3332495A (en) Methods of inhibiting ulcerative mucositis
EP1031287A4 (en) Drinking water additive for birds and method of administering the same
AP2000001780A0 (en) Apparatus and method for the purification of water
ZA988934B (en) Method and composition for inhibiting corrosion
HUP9904243A3 (en) Method for inhibiting the expression of fas
HUP0102259A3 (en) Methods of inhibiting corrosion using isomers of chloro-methylbenzotriazole
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
PL333984A1 (en) Method of obtaining n-substituted 3-hydroxypyrazoles
AU6422494A (en) Method for ultra-trace level analysis of water
GB9615363D0 (en) Apparatus for the combatting of underwater growth on submerged structures
PL322111A1 (en) Method of obtaining locarbeph monohydrate
GB9615262D0 (en) Method for inhibiting the growth of microorganisms in an aqueous medium
HU9701918D0 (en) Method and composition for removing of phosphor contain of water
PL303949A1 (en) Method of obtaining inhibitors of cysteine pepsidases
HU9700098D0 (en) Method and apparatus for improving the magnesium contain of water
PL301910A1 (en) Method of obtaining volatile corrosion inhibitors